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Background: Number of orphan medicinal products on the market and number of rare disease patients, taking
these usually expensive products, are increasing. As a result, budget impact of orphan drugs is growing. This factor,
along with the cost-effectiveness of orphan drugs, is often considered in the reimbursement decisions, directly
affecting accessibility of rare disease therapies. The current study aims to assess the budget impact of orphan drugs
in Latvia.
Methods: Our study covered a 5-year period, from 2010 to 2014. Impact of orphan drugs on Latvian budget was
estimated from the National Health Service’s perspective. It was calculated in absolute values and relative to total
pharmaceutical market and total drug reimbursement budget. A literature review was performed for comparison
with other European countries.
Results: Orphan drug annual expenditure ranged between EUR 2.065 and 3.065 million, with total 5-year
expenditure EUR 12.467 million. It constituted, on average, 0.84 % of total pharmaceutical market and 2.14 % of
total drug reimbursement budget, respectively. Average annual per patient expenditures varied widely, from EUR
1 534 to EUR 580 952. The most costly treatment was enzyme replacement therapy (Elaprase) for MPS II. Glivec had
the highest share (34 %) of the total orphan drug expenditure. Oncological drugs represented more than a half of
the total orphan drug expenditure, followed by drugs for metabolic and endocrine conditions and medicines for
cardiopulmonary diseases. Three indications: Ph+ CML, MPS II, and PAH accounted for nearly 90 % of the total
orphan drug expenditure.
Conclusions: Budget impact of orphan drugs in Latvia is very small. It increased slightly over a period of five years,
due to the slight increase in the number of patients and the number of orphan drugs reimbursed. Current Latvian
drug reimbursement system is not sufficient for most orphan drugs.
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Orphan drugs are medicinal products intended for the
treatment, diagnosis or prevention of life-threatening or
seriously debilitating rare conditions affecting less than
one person in 2 000 individuals across the European
Union [1]. Most of them are indicated for treatment of
oncological conditions [2–5], followed by metabolic and
endocrine diseases (including lysosomal storage diseases)
and cardiovascular disorders (particularly pulmonary ar-
terial hypertension). By the end of 2014, there were
more than a thousand positive opinions on orphan* Correspondence: konstantins.logviss@gmail.com
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marketing authorization in the EU [6, 7].
Orphan medicinal products are often highly expensive
[8]. Factors, such as costs of research and development,
marketing exclusivity, lack of alternative therapies, dis-
ease severity, and small market size can affect orphan
drug prices. Moreover, orphan drugs for treatment of
diseases with lower prevalence generally have higher
costs than drugs indicated to treat more common condi-
tions [3, 9]. Especially drugs for ultra-orphan diseases
[10], with a prevalence of less than 1 per 50 000 persons,
are highly expensive. In fact, orphan designated drugs
tend to have higher prices than non-designated drugs
for rare diseases [11]. Standard cost-effectiveness criteria
are often not applicable to orphan drugs [4, 8], consider-
ing the high costs of these medicines and often modest
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pressure on decision makers. Given current fiscal con-
straints and financial uncertainty around orphan drugs,
health authorities are increasingly concerned about the
growth in orphan drug expenditure and its impact on
their limited budgets. On the one hand, budget impact
for an individual orphan drug is usually small [12, 13],
due to the limited numbers of patients. The majority of
orphan drugs have relatively low sales [13], except few
high-cost orphan drugs. Though, budget impact for or-
phan drugs altogether might be considerable [12, 14]. As
a result, the number of studies conducted in this field at
the European level is increasing. An early European
study showed that orphan medicinal products accounted
for 0.7 % and 1 % of total drug budgets in France and
the Netherlands in 2004 [9], and it was anticipated to in-
crease to 6–8 % by 2010. Another study focused on five
European countries with the highest drug expenditures,
and found that the average overall impact of orphan
drugs was 1.7 % of total drug spending in 2007 [3]. The
impact of orphan drugs was predicted to increase from
3.3 % of the total European pharmaceutical market in
2010 to a peak of 4.6 % in 2016 [14]. In Europe, total
budget impact of ultra-orphan drugs for non-oncological
diseases was estimated to be EUR 20 625 million over
10 years (2012–2021) [15]. In Belgium, orphan drugs
represented 1.9 % (EUR 66 million) of total drug ex-
penditure in 2008 [16, 17], and it was estimated to grow
to about 4 % (EUR 162 million) in 2013. The share of
total pharmaceutical expenditure spent on orphan drugs
in the Netherlands almost quadrupled, from 1.1 % in
2006 to 4.2 % in 2012 (from EUR 61.2 to 260.4 million)
[12]. In 2012, budget impact of orphan medicinal prod-
ucts represented 2.5 % of total pharmaceutical market in
Sweden and 3.1 % in France [13]. And it was forecasted
to grow to 4.1 % in Sweden and 4.9 % in France by 2020.
Finally, in Bulgaria, which was a pioneering country in
Eastern Europe in adopting a national plan and imple-
menting registers for rare diseases, expenditure for out-
patient rare disease therapies was around 8 % of the
total National Health Insurance Fund’s expenditure for
medications in 2012–2014 (about EUR 32 million in
2013) [5].
Orphan drug availability, accessibility, pricing and re-
imbursement policies differ between European countries
[4, 18, 19]. Some countries consider the budget impact and
cost-effectiveness of orphan drugs in their reimbursement
decisions. For example, in France, Italy, the Netherlands,
the UK, and Serbia reimbursement is based on both, cost-
effectiveness and budget impact. In contrast, Belgium and
Bulgaria do not consider the cost-effectiveness, while the
budget impact analysis is not required in Sweden.
In Latvia, there is no specific policy in place for the pri-
cing and reimbursement of orphan medicinal products[20, 21]. Cost-effectiveness and expected budget impact
are evaluated for each medicine before inclusion in the re-
imbursement list. Drug prices are compared with prices in
selected European countries. Orphan drugs can be pro-
vided through the three main mechanisms. Firstly, the re-
imbursement system covers medicinal products included
in the national reimbursement drug list. Medicines can
also be reimbursed within the framework of individual
reimbursement system, with annual limit of EUR 14
229 (previously LVL 10 000) per patient. Additionally,
orphan drugs for children are provided through the
state funded program “Medicinal treatment for chil-
dren with rare diseases”.
It has been shown that a low gross domestic product
(GDP) value and availability of a formal health technol-
ogy assessment (HTA) organization have negative influ-
ence on orphan drug market uptake [22]. Budget impact
analyses conducted so far focused predominantly on the
old EU countries with a high GDP (markets with high
drug expenditures) or Europe as a whole [3, 9, 12–17].
In contrast, Latvian study could provide an insight on
the situation in a small Eastern European country with a
low GDP. The current study aims to assess the budget
impact of orphan drugs in Latvia and compare it with
other European countries.
Methods
Our study covered a 5-year period, from 2010 to 2014.
Orphan drugs were defined as the medicinal products
with European marketing authorization and European
orphan designation granted by the European Medicines
Agency (EMA) and active during the studied period.
European Community register of designated orphan me-
dicinal products and the EMA database of rare disease
designations were used to identify orphan drugs autho-
rized in the EU. Some drugs, that were originally desig-
nated orphan medicines, are no longer considered
orphan drugs in Europe. These products were with-
drawn from the European Community register of desig-
nated orphan medicinal products, either at the end of
the period of market exclusivity or on the request of the
sponsor. We included such drugs in the study until the
end of the year when the last orphan indication of the
product was withdrawn, i.e. the last year these drugs
were formally considered orphan medicines in Europe.
For instance, Sutent was withdrawn from the European
Community register in 2008, and was, therefore, out of
the scope of the current study, which covered the period
of 2010–2014.
Impact of orphan drugs on Latvian budget was calcu-
lated from the National Health Service’s (NHS) perspective.
A particular orphan drug can have multiple indications, or-
phan and non-orphan. For such drugs, only expenditures
related to orphan indications were taken into account. For
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reimbursement lists and the individual reimbursement, we
used the NHS annual reports on the use of funds for
reimbursement of outpatient drugs and medical devices.
Children’s Clinical University Hospital (CCUH) purchase
procedure reports on the “Medicinal treatment for children
with rare diseases” program (financed by the NHS) were
analyzed to assess orphan drugs provided through this
pathway. A particular orphan medicinal product can be
provided through multiple reimbursement mechanisms.
For such products, double counting was excluded. Total
drug reimbursement budget (orphan and non-orphan
products) was calculated as a sum of funds covering the re-
imbursement lists, individual reimbursement and the
CCUH program. This information was available from the
NHS annual public reports. For the information on total
pharmaceutical market (total turnover of medicines) we
used “Statistics on Medicines Consumption” annually pub-
lished by the State Agency of Medicines of Latvia. Budget
impact of orphan drugs was calculated by dividing the
expenditures covering orphan drugs by the total pharma-
ceutical market and the total drug reimbursement budget,
respectively.
Euro (EUR) was introduced in Latvia on 1st January
2014, thus no currency conversion was required for this
year. For the period 2010–2013, we used the official
exchange rate defined by the Bank of Latvia for the na-
tional currency (Latvian lat – LVL). Starting from 2005,
the Bank of Latvia set a fixed exchange rate 1 EUR =
0.7028 LVL, which was actual until the end of 2013.
When the literature review was performed, for compari-
son with other countries, we used xe.com EUR exchange
rates, if orphan drug expenditures were expressed in
other currencies, e.g. British pounds (GBP).
Annual expenditure per patient was calculated by div-
iding the annual expenditure covering orphan drug re-
imbursement by the number of patients receiving these
medications. For the individual reimbursement and the
CCUH program, the number of patients receiving par-
ticular drugs was known from the NHS annual reports
on the use of funds for reimbursement of outpatient
drugs and medical devices and the NHS annual public
reports, respectively. For drugs included in one of the
reimbursement lists, the number of patients was esti-
mated by using the EMA approved summary of product
characteristics (SPC) and the number of drug packages
reimbursed by the NHS. The SPC was used to identify
the recommended maintenance daily dose used for
drug's main indication in adults. This dose was further
converted to the number of pharmaceutical forms (e.g.
tablets or capsules). Then, the content of a single pack-
age was divided by the number of pharmaceutical forms
required per day, to find the duration of treatment
(number of days) covered by one package. It was furthercalculated how many packages are required for one year
treatment period. Number of patients receiving a par-
ticular drug was estimated by dividing the total number
of drug packages reimbursed by the NHS by the number
of packages required for one patient per year.
We performed a literature review to compare the
budget impact of orphan drugs in Latvia with other
European countries. The budget impact of orphan drugs
was expressed in absolute figures (million EUR) and
relative to the total pharmaceutical market. If a study re-
ported only the budget impact of orphan drugs as a per-
centage of the total pharmaceutical market, the absolute
figures were calculated taking into account the numbers
representing the total pharmaceutical market, as re-
ported in the study. If multiple studies were available for
a country, the most recent study was selected. If a study
reported actual (observed) data and data forecasted for
the future, the observed data for the latest year were
preferred. The World Bank’s data on the population and
GDP (PPP) per capita were used for each country for
the year of interest. We also identified the number of or-
phan drugs with active marketing authorizations in the
EU and converted the orphan drug expenditure into ex-
penditure per 100 000 inhabitants.
Results
Twenty one different orphan drugs were reimbursed
through the three reimbursement pathways during the
period covered by the study (Table 1). The number of
orphan medicines reimbursed per year increased slightly,
from 11 drugs in 2010 to 15 drugs in 2014. Four drugs
were provided through multiple reimbursement mecha-
nisms: Sprycel and Wilzin were provided individually
prior to inclusion in the reimbursement list; Glivec was
simultaneously reimbursed individually and through the
reimbursement list; Cystadane was provided through the
individual reimbursement and the CCUH program.
Nplate and Mozobil were included in the reimbursement
list in 2014 and 2015, respectively, however so far these
products were reimbursed individually. Aldurazyme and
Sutent were reimbursed after the loss of orphan drug status
in the EU, and were, therefore, excluded from the study.
Orphan drug annual expenditure ranged between EUR
2.065 and 3.065 million, with total 5-year expenditure
EUR 12.467 million (Table 2). It constituted, on average,
0.84 % of the total pharmaceutical market annually, with
a maximum 1.04 % seen in 2012, followed by a mini-
mum 0.70 % in 2013. These peak and bottom values can
be explained by the fact that Glivec was withdrawn from
the European Community register of designated orphan
medicinal products in 2012, and was no longer consid-
ered orphan medicine in the EU. Additionally, after the
patent expiration in 2013, imatinib generics became
available and practically replaced the brand drug from
Table 1 Orphan drugs reimbursed in Latvia
Reimbursement Lists
Trade Name Active Substance Orphan Indication Inclusion Date Reimbursement List
Glivec* Imatinib Ph+ CML; Ph+ ALL; MDS/MPD; GIST; DFSP; HES and CEL April 2013 List A (previously List C)
Nplate Romiplostim Idiopathic thrombocytopenic purpura (ITP) March 2014 List B
Wilzin* Zinc Wilson’s disease June 2014
Sutent* Sunitinib GIST December 2014
Sprycel Dasatinib Ph+ CML; Ph+ ALL October 2010 List C
Tasigna Nilotinib Ph+ CML December 2010
Mozobil Plerixafor HSCT in patients with lymphoma and multiple myeloma January 2015
CCUH Program
Trade Name Active Substance Orphan Indication
Elaprase Idursulfase Hunter syndrome (Mucopolysaccharidosis II – MPS II)
Myozyme Alglucosidase alpha Pompe disease
Aldurazyme* Laronidase Mucopolysaccharidosis I (MPS I)
Kuvan Sapropterin Hyperphenylalaninaemia (HPA) in patients with phenylketonuria (PKU) or tetrahydrobiopterin (BH4) deficiency
Cystadane Betaine Homocystinuria
Increlex Mecasermin Primary insulin-like growth factor 1 deficiency (primary IGFD)
Votubia Everolimus Renal angiomyolipoma and subependymal giant cell astrocytoma associated with tuberous sclerosis complex (TSC)
Individual Reimbursement
Trade Name Active Substance Orphan Indication
Revatio Sildenafil Pulmonary arterial hypertension (PAH)
Volibris Ambrisentan PAH
Tracleer* Bosentan PAH; systemic sclerosis
Nexavar Sorafenib Hepatocellular carcinoma; renal cell carcinoma; differentiated (papillary/follicular) thyroid carcinoma
Atriance Nelarabine T-ALL and T-LBL
Sutent* Sunitinib GIST
Glivec* Imatinib Ph+ CML; Ph+ ALL; MDS/MPD; GIST; DFSP; HES and CEL
Sprycel Dasatinib Ph+ CML; Ph+ ALL
Mozobil Plerixafor HSCT in patients with lymphoma and multiple myeloma
Arzerra Ofatumumab Chronic lymphocytic leukaemia (CLL)
Nplate Romiplostim ITP
Revolade* Eltrombopag ITP
Exjade Deferasirox Chronic iron overload due to blood transfusions in patients with beta thalassaemia major, other anaemias, and
non-transfusion-dependent thalassaemia syndromes
Wilzin* Zinc Wilson’s disease
Cystadane Betaine Homocystinuria
Diacomit Stiripentol Dravet’s syndrome (Severe myoclonic epilepsy in infancy – SMEI)
Drugs withdrawn from the European Community register of designated orphan medicinal products
Trade Name Active Substance Withdrawal Date Reason of Withdrawal
Aldurazyme Laronidase June 2013 End of the period of market exclusivity
Wilzin Zinc October 2014
Revolade Eltrombopag January 2012 Request of the sponsor
Sutent Sunitinib July 2008
Glivec Imatinib November 2011 End of the period of market exclusivity (for Ph+ CML)
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Table 1 Orphan drugs reimbursed in Latvia (Continued)
April 2012 Request of the sponsor (for other indications)
Tracleer Bosentan May 2012 End of the period of market exclusivity (for PAH)
April 2014 Request of the sponsor (for systemic sclerosis)
*Drugs withdrawn from the European Community register of designated orphan medicinal products





Expenditure (EUR) Share of total
expenditure
Reimbursement
category2010 2011 2012 2013 2014 Total
Atriance Nelarabine 24 773 24 773 0.20 % Individual
reimbursement
Nexavar Sorafenib 16 418 12 040 23 806 17 786 14 229 84 278 0.68 %
Revatio Sildenafil 104 742 147 370 219 252 340 536 480 685 1 292 585 10.37 %
Volibris Ambrisentan 52 172 87 744 142 289 128 058 163 633 573 897 4.60 %
Exjade Deferasirox 5 726 7 329 13 055 0.10 %
Sprycel Dasatinib 60 450 60 450 0.48 %
Wilzin Zinc 1 317 169 1 486 0.01 %
Cystadane Betaine 1 038 3 142 2 094 4 327 6 560 17 161 0.14 %
Diacomit Stiripentol 6 696 8 940 14 354 11 424 16 947 58 360 0.47 %
Glivec Imatinib 47 731 68 608 116 340 0.93 %
Arzerra Ofatumumab 27 830 27 830 0.22 %
Mozobil Plerixafor 12 796 25 592 38 389 0.31 %
Nplate Romiplostim 13 687 13 687 0.11 %
Revolade Eltrombopag 3 790 3 790 0.03 %
Tracleer Bosentan 12 697 12 697 0.10 %
Glivec Imatinib 1 373 374 1 481 110 1 252 280 4 106 764 32.94 % List A
(previously List C)
Sprycel Dasatinib 202 997 296 703 412 538 524 119 1 436 357 11.52 % List C
Tasigna Nilotinib 149 561 275 615 285 964 711 140 5.70 %
Wilzin Zinc 1 534 1 534 0.01 % List B
Elaprase Idursulfase 418 275 501 228 596 232 681 408 707 619 2 904 762 23.30 % CCUH program
Kuvan Sapropterin 173 374 173 374 213 828 560 575 4.50 %
Cystadane Betaine 6 265 6 265 6 416 18 945 0.15 %
Increlex Mecasermin 94 257 93 557 93 820 281 634 2.26 %
Myozyme Alglucosidase
alpha
71 548 71 548 0.57 %
Votubia Everolimus 34 802 34 802 0.28 %
All Orphan Drugs 2 064 981 2 550 574 3 064 669 2 144 887 2 641 727 12 466 838
Total Pharmaceutical
Market
276 690 000 290 190 000 295 480 000 307 590 000 316 040 000 Average
Share of Total
Pharmaceutical Market
0.75 % 0.88 % 1.04 % 0.70 % 0.84 % 0.84 %
Total Drug Reimbursement
Budget
105 911 722 118 204 402 117 007 689 117 384 880 122 326 421 Average
Share of Total Drug
Reimbursement
1.95 % 2.16 % 2.62 % 1.83 % 2.16 % 2.14 %
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resented, on average, 2.14 % of the total drug reimburse-
ment annual budget, with maximal (2.62 %) and
minimal (1.83 %) values also observed in 2012 and 2013.
If Glivec was excluded from the study, the orphan drug
expenditure would increase constantly, from EUR 0.692
million to EUR 2.642 million (Fig. 1). It corresponds to
more than a threefold increase, from 0.25 % to 0.84 % of
the total pharmaceutical market within 5 years.
In a 5-year period, number of patients receiving orphan
drugs increased by 60 %, from 80 to 128 patients. It chan-
ged in a similar manner as the orphan drug expenditure,
depending on Glivec exclusion (Fig. 2). Until 2012, Glivec
had the highest annual number of patients, varying be-
tween 40 % and 56 % of all patients in 2010–2012,
whereas Revatio had the highest growth in the number of
patients, with more than a fourfold increase within 5 years
(from 18 to 77 patients, i.e. 60 % of all patients in 2014).
The average overall annual expenditure per patient de-
creased by 20 %, from EUR 25 812 to EUR 20 638.
Average annual per patient expenditures varied widely,
from EUR 1 534 for Wilzin to EUR 580 952 for Elaprase,
and averaged at EUR 23 701 (Table 3). Annual budget
for Elaprase grew constantly, with a peak per patient ex-
penditure reaching EUR 707 619 in 2014. More than a
half of the total orphan drug expenditure within 5 years
was the expenditure related to two medications, Glivec
(33.9 %) and Elaprase (23.3 %) (Fig. 3). Moreover, con-
sidering the fact that Glivec was included in the study
until the end of 2012, these two products generated
86.8 %, 79.6 %, and 62.6 % in three consecutive years
2010–2012.
Oncology drugs represented 52.99 % of the total or-
phan drug expenditure, followed by drugs for metabolic
and endocrine conditions (30.94 %) and medicines for












Expenditure (all orphan drugs
Fig. 1 Orphan drug expenditurePh+ CML treatment agents (Glivec, Sprycel, and Tasigna)
generated 50.97 % of the total orphan drug expenditure,
followed by Elaprase for MPS II (23.30 %) and drugs for
PAH (Revatio, Volibris, and Tracleer), with 15.07 % (Fig. 4).
Although, these drugs were provided through different re-
imbursement mechanisms: the total expenditure covering
orphan drugs provided through the reimbursement lists
was almost exclusively represented by the agents for Ph+
CML (99.98 %), whereas Elaprase and drugs for PAH
amounted to 75.01 % of the CCUH program and 80.35 %
of the individual reimbursement orphan drug expendi-
tures, respectively.
Budget impact of orphan drugs as a proportion of the
total pharmaceutical market is 3–5 times smaller in
Latvia than in other recently studied (in 2012) markets
(Table 4). Latvian population is 5–40 times smaller and
GDP (PPP) per capita is 1.5–2 times smaller than in
other countries. Consequently, the orphan drug expend-
iture per 100 000 inhabitants is 2–12 times smaller in
Latvia. This difference is remarkable, considering the
time lag between the studies and the different number of
orphan drugs authorized in the EU (44 orphan drugs in
2007 vs. 78 in 2014). For example, more than a million
EUR was spent per 100 000 inhabitants in three coun-
tries in 2012, when the number of orphan drugs on the
market was closer to the number seen in 2014.
A study by Picavet et al. included Latvia in the European
analysis of orphan drug market uptake [22]. Latvia was
clustered with Hungary and Poland, as countries with a
low GDP and a formal HTA organization. This cluster
had the lowest orphan drug market volumes and sales.
Moreover, in Latvia, only EUR 8 000 was spent per 100
000 inhabitants on orphan medicines, compared to ap-
proximately EUR 560 000 in France. The share of orphan
drug sales relative to the total drug market sales varied
from 0.07 % in Latvia to 1.90 % in Estonia. These results2 0 1 2 2 0 1 3 2 0 1 4




























Patients (all orphan drugs)
Patients (excl. Glivec)
Average expenditure per patient (all orphan drugs)
Average expenditure per patient (excl. Glivec)
Fig. 2 Number of patients and average annual expenditure per patient
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should be clarified here. Only 17 orphan drugs were in-
cluded in the analysis, out of which only five drugs were
launched in Latvia. Moreover, orphan drugs which gener-
ated the highest expenditures in our study (Glivec,
Elaprase, and Revatio) were not included. Therefore, theTable 3 Average annual expenditure per patient
Trade Name Active Substance Average annual expenditure
per patient (EUR)
Glivec Imatinib 30 420; 7 756a
Sprycel Dasatinib 49 530; 60 450a
Tasigna Nilotinib 47 409
Wilzin Zinc 1 534; 495a
Mozobil Plerixafor 12 796
Nplate Romiplostim 13 687
Elaprase Idursulfase 580 952
Myozyme Alglucosidase alfa 71 548
Increlex Mecasermin 40 233
Kuvan Sapropterin 43 121
Votubia Everolimus 34 802
Cystadane Betaine 6 315; 3 432a
Revatio Sildenafil 6 185
Volibris Ambrisentan 10 434
Tracleer Bosentan 12 697
Diacomit Stiripentol 7 295
Arzerra Ofatumumab 13 915
Atriance Nelarabine 12 386
Nexavar Sorafenib 10 535
Exjade Deferasirox 6 527
Revolade Eltrombopag 3 790
aIndicates the individual reimbursement, if a drug was provided through
multiple reimbursement mechanismsreal market uptake of all orphan drugs authorized in the
EU is much higher, although it relates to all European
markets, rather than specifically to Latvia. Our study
found that the orphan drug expenditure constituted, on
average, 0.84 % of the total pharmaceutical market in
Latvia. It increased very slightly over a period of five years,
remaining under the 1 % threshold, due to the slight
increase in the number of patients and the number of
orphan drugs reimbursed, whereas the average annual
expenditure per patient decreased. In contrast, in the
Netherlands, budget impact of orphan drugs increased
almost fourfold over a period of six years [12], while both,
the number of patients and the number of orphan drugs,
almost quadrupled.
Orphan drug expenditures in Latvia are characterized
by extremely small numbers, considering a trend of or-
phan drug budget impact to increase, due to the growing
number of orphan medicinal products on the market
and the growing number of patients taking these, usually
expensive, products. Similar figures were reported only
in the very first budget impact studies, when the number
of orphan drugs on the European market was small.
Thus, orphan medicinal products accounted for 0.7 %
and 1 % of total drug budgets in France and the
Netherlands in 2004 [9], when only 15 orphan drugs
were authorized in the EU. More recent analyses showed
greater impact of orphan drugs on total pharmaceutical
market. For instance, the share of total pharmaceutical
expenditure spent on orphan drugs in the Netherlands
increased markedly, from 1.1 % in 2006 to 4.2 % in 2012
[12]. A study of five European countries, with the high-
est drug expenditure, found that the average overall im-
pact of orphan drugs was 1.7 % of total drug spending in
2007 [3]. In Belgium, orphan drugs accounted for 1.9 %
of total drug expenditure in 2008 [16, 17], and it was es-



























































Fig. 3 Orphan drugs with the highest total expenditure
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authorizations at the time of these two studies, in 2007–
2008. Later, Schey et al. predicted the impact of orphan
drugs to increase from 3.3 % of the total European
pharmaceutical market in 2010 to a peak of 4.6 % in 2016
[14]. Finally, in 2012, budget impact of orphan medicinal
products accounted for 2.5 % of total pharmaceutical
market in Sweden and 3.1 % in France [13]. These budget
impact analyses focused predominantly on the old EU
countries with a high GDP. The current study demon-
strated that budget impact of orphan drugs in Latvia, as a
small Eastern European country with a low GDP and,
hence, healthcare budget constraints, is considerably lower.
It is, however, complicated to compare the budget impacts
of orphan medicines in different countries due to a lack of






Fig. 4 Orphan drug indications with the highest total expendituredifferences in pricing and reimbursement systems, and
time lag between the studies.
Different studies used different approaches and
sources of information for the analyses, such as the
estimates of budget impact submitted by pharmaceutical
companies in the original reimbursement files (or revi-
sion files submitted later, when more recent information
is available), data published by the HTA organizations,
NHS or other payers, and IMS (Intercontinental Medical
Statistics) Health data. IMS Health database is widely
used to evaluate and compare drug markets. Though, it
has been pointed out that there are some differences in
data quality between countries [22]. Moreover, real
utilization of medicines may differ from that reflected in
sales data. There are both, retrospective and forecasting,
types of budget impact analyses. Actual data are used as a
basis for forecasts, while forecasting nature of the analyses
usually leaves much uncertainty, depending on multiple
variables, such as number of orphan designations and
marketing authorizations, drug costs, number of patients,
reimbursement decisions, availability of therapeutic alter-
natives, and competition after expiration of marketing ex-
clusivity and patent protection. Budget impact analyses
have been criticized for their simplicity [4, 17, 23].
The analyses are generally limited to evaluating the
impact of drug costs, rather than total treatment
costs. If an orphan drug has multiple indications,
budget impact across all indications is often not con-




Availability and accessibility of orphan drugs in a par-
ticular country depend on multiple factors, such as mar-
keting strategy of pharmaceutical companies, market
attractiveness, pricing and reimbursement policies.
Table 4 Budget impact of orphan drugs in European countries
Country Budget impact of OD




Year Number of OD with





OD expenditure per 100
000 inhabitants (EUR)a
UK 1.0 % [3] 162.0 2007 44 61.32 37 507 264 188
Italy 1.5 % [3] 235.5 2007 44 58.44 33 731 402 977
Spain 2.0 % [3] 256.0 2007 44 45.23 32 807 565 996
Germany 2.1 % [3] 525.0 2007 44 82.27 36 782 638 143
Belgium 1.9 % [16, 17] 66.2 2008 49 10.71 37 847 618 114
Netherlands 4.2 % [12] 260.4 2012 64 16.75 46 379 1 554 627
France 3.1 % [13] 1054.0 2012 64 65.64 37 256 1 605 728
Sweden 2.5 % [13] 107.2 2012 64 9.52 43 869 1 126 050
Latvia 0.84 % 2.64 2014 78 1.99 22 873 132 663
OD orphan drugs, MA marketing authorization, GDP (PPP) per capita gross domestic product per capita based on purchasing power parity
aIn the year of interest
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main mechanisms in Latvia: the reimbursement list, the
individual reimbursement, and the CCUH program “Me-
dicinal treatment for children with rare diseases”. The
national reimbursement list consists of three parts [20, 21]:
List A covers therapeutically equivalent drugs (generics);
List B consists of medicines without therapeutic equiva-
lents; and List C contains expensive drugs, for which the
annual costs exceed EUR 4 269 (previously LVL 3 000) per
patient, and the manufacturer is obliged to cover treatment
expenses (not less than 10 %) for a certain number of pa-
tients. This provision is an important tool to manage the
costs of expensive medicines, although it is not intended
specifically for orphan drugs. For example, Glivec was
additionally covered by the company for five patients in
2010 and 2011 [24, 25]. Orphan drugs are usually included
in the List C. Starting from 2014, some orphan drugs are
also included in the List B (Table 1). The individual reim-
bursement can be provided only if a disease is not included
in the reimbursement list, or the disease is included
in the list, but there are no drugs included in the re-
imbursement list for treatment of this condition. Not
more than 2 % of the national drug reimbursement
budget is intended to the individual reimbursement,
with a limitation up to EUR 14 229 (previously LVL
10 000) per patient per year.
Orphan drugs reimbursed in Latvia can be divided in
two groups. Drugs provided through the reimbursement
lists and the CCUH program can generally be consid-
ered fully accessible to patients, whereas drugs provided
through the individual reimbursement are frequently
only partially accessible, considering the annual limit of
EUR 14 229 per patient. This threshold is too low. Only
Revatio, Diacomit, Cystadane, Wilzin, and Mozobil can
be fully provided within this limit. Other orphan drugs
should be additionally covered by the manufacturers,
charities or patients themselves.Market size
Number of orphan medicines reimbursed per year through
the three reimbursement pathways increased slightly,
reaching 15 drugs in 2014. It is less than 20 % out of 78
orphan drugs with active marketing authorizations in the
EU in the same year. The remaining drugs are practically
inaccessible to rare disease patients. Decisions to launch
the product on the market and to apply for the reimburse-
ment are taken by the manufacturer. Market size plays a
crucial role in these decisions. The absolute number of rare
disease patients treated in Latvia is very low. Some orphan
drugs (including Elaprase) were reimbursed for a single pa-
tient. There might be no diagnosed patients eligible for the
treatment with a particular orphan drug. In 2014, a total of
128 patients received orphan drugs in Latvia. In contrast,
in the Netherlands, Glivec alone was provided to 1 485 pa-
tients in 2012 [12]. The low number of patients along with
the fiscal constraints make Latvian market less attractive
for the manufacturers of orphan drugs.
Orphan drugs are generally less reimbursed in new EU
Member States [9], whose health care budgets are
considerably lower than those of older Member States.
Bulgarian study reported similar findings, where over
two-thirds of orphan drugs were not reimbursed in 2014
[5]. Authors compared this number with other EU
Member States, where about 80 % of orphan medicinal
products are incorporated in the healthcare systems. They
also pointed out that time delay from the EU marketing
authorization to the positive reimbursement decision is
much longer in Bulgaria than in other countries. Bulgaria
is bigger country than Latvia, with a population 7.2 mil-
lion vs. 2.0 million in Latvia [26], and consequently more
rare disease patients. According to the Eurordis survey, es-
pecially smaller countries suffer from longer delay in avail-
ability of orphan medicines [27]. Differences in the annual
per patient costs for a given orphan drug can reach 70 %
between the EU countries [9]. Besides, orphan drug prices
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as the Baltics, than in the bigger states, such as Poland or
the Czech Republic.
Therapeutic areas of orphan drugs
Oncological drugs represented more than a half of the
total orphan drug expenditure, followed by the drugs for
metabolic and endocrine conditions and the medicines
for cardiopulmonary diseases. Those are generally the
main therapeutic areas of orphan drugs [2–5]. In 2010,
oncological and haematological disorders accounted for
57 % of the total orphan drug costs in Europe [14].
Within these therapeutic areas, there are some indica-
tions, for which either multiple orphan drugs or highly
expensive orphan drugs are available. Thereby, nearly
90 % of the total orphan drug expenditure in our study
covered only three indications: Ph+ CML, MPS II, and
PAH. One of such orphan drugs for Ph+ CML treat-
ment, Glivec, is a blockbuster anticancer drug with mul-
tiple orphan indications. It generated 34 % of the total
orphan drug expenditure within 5 years. Similar results
were reported in other studies. The majority of orphan
drugs have relatively low sales [13], except few high-cost
orphan drugs. For instance, the total sales of Glivec
reached EUR 679 million in the five biggest European
countries in 2007 [3]. It was more than 40 % of the total
orphan drug expenditure. Moreover, if the expenditures
relating to three drugs (including imatinib) with the
highest sales were excluded from the study, budget impact
of the remaining orphan medicines would be more than
halved. In our study, it would be enough to exclude just
two medications (Glivec and Elaprase) to reach the same
result. In a Dutch study, Glivec also had the highest cumu-
lative budget impact (EUR 251.2 million) [12]. It accounted
for 34 % of the total orphan drug expenditure between
2000 and 2012 in Sweden, and 27 % in France [13].
Intellectual property
Loss of intellectual property, such as expiration of mar-
keting exclusivity and patent protection, can greatly
affect drug prices and result in an increased competition.
As reported by Onakpoya et al., for orphan drugs, where
generic alternatives were available, the branded products
were from 1.4 to 82 000 times more expensive [10].
However, it is not clear yet whether the orphan drug
market is attractive enough for generic companies to
enter the field of rare diseases. Orphan drug market has
distinctive features, characterized primarily by specific
European regulation, small number of patients, and high
drug prices. In addition, orphan medicines have remarkably
higher proportion of large-molecule than small-molecule
agents [2], compared to non-orphan drugs. Since the bio-
logicals are currently less subjected to generic (biosimilar)
competition than the small molecules, they can maintainhigh economic value even after the patent expiration. The
current study demonstrated that generic companies may
have a big interest in some orphan drugs. Starting from
May 2013, Glivec was moved to the reimbursement List A,
because generic drugs became available, that changed pre-
scribing and reimbursement criteria for imatinib. In fact,
cheaper imatinib generics practically replaced the brand
drug from the reimbursement system. In 2014, the reim-
bursement expenditure covering Glivec was only EUR 2
904, compared to the annual expenditure varying between
EUR 1.321 and 1.529 million in 2010–2012. However,
Glivec should not be considered as a model for all orphan
drugs, since it is a small molecule, used for multiple
indications, and known for a long time as a classical block-
buster orphan drug. Not all orphan medicines are expected
to cause such interest from the generic companies. It
should be noted that orphan drugs were excluded from the
analysis when the period of market exclusivity ended. It is
likely that these drugs will still have a budgetary impact, as
patients will continue using them. However, these products
were removed from the Community register of orphan me-
dicinal products and are no longer considered orphan med-
icines in Europe.
Enzyme replacement therapy
Annual per patient costs can vary broadly between dif-
ferent orphan drugs: EUR 1 534–580 952 (current
study); EUR 6 000–300 000 [9]; EUR 331–337 501 [3];
EUR 1 251–407 631 [14]; GBP 726–378 000 [10]. In the
present study, the two most expensive drugs, on the an-
nual per patient basis, were Elaprase and Myozyme.
Both medicines were provided through the CCUH pro-
gram, as enzyme replacement therapy (ERT) for MPS II
and Pompe disease. The program provided ERT also for
Gaucher disease (Cerezyme) and MPS I (Aldurazyme),
however these products are not considered orphan drugs in
Europe. In fact, if Cerezyme and Aldurazyme were included
in the study, they would be among the most expensive
medicines, with the average annual per patient expenditures
EUR 213 716 and EUR 157 248, respectively, and more
than EUR 1 million of the total expenditure in 5 years.
ERT for Gaucher disease was the most costly per patient
therapy in Israel [28]. To decrease the costs authors
recommended to apply criteria of disease severity, use
low-dose regimen or even “drug vacations”. In Bulgaria,
MPS and glycogen storage disease (conditions treated with
ERT) were the two rare diseases with the highest costs per
patient [5]. Elaprase and Naglazyme had the highest
estimated annual costs among the inpatient orphan drugs
in the Netherlands [29], whereas Myozyme had the high-
est budget impact. However, it appears that ERT is not the
most expensive treatment worldwide. Soliris (eculizumab),
for the treatment of paroxysmal nocturnal haemoglobin-
uria, was mentioned as the most expensive drug in the
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The latest price record was set by Glybera (alipogene
tiparvovec) [30], the first gene therapy drug approved by
the EMA for lipoprotein lipase deficiency in 2012, with a
cost over EUR 1 million per patient. Both drugs are desig-
nated orphan medicinal products in the EU.
Future budget impact of orphan drugs
Orphan drug expenditure grew faster (with annual growth
rates 20–25 % in the years not affected by the change in
the status of Glivec) than the total pharmaceutical market
(annual growth rates 2–5 %) and the total drug reimburse-
ment budget (Table 5). The only negative growth (−30 %)
was observed in 2012–2013, that was caused by the
change in the status of Glivec. Based on the observed
trends, it is likely that the budget impact of orphan drugs
in Latvia will follow the general European tendencies and
will continue to grow in the future, both in absolute num-
bers and relative to the total pharmaceutical market. This
assumption is strengthened by the fact that the number of
orphan drugs will only increase in the future, both at
European level (14 new orphan drugs were approved by
the EMA in 2015) and at Latvian national level (3 orphan
drugs were included in the reimbursement list in 2014–
2015). Other studies have shown that the budget impact
of orphan drugs in European countries is increasing, how-
ever the growth rates are decreasing over time [12–14],
due to expiration of patents and marketing exclusivity of
existing orphan drugs. It is, therefore, likely that the
budget impact of orphan drugs in Latvia will remain sus-
tainable and relatively small in the long run. Although, it
should be pointed out that currently available data is too
limited to create a detailed and well validated model for
the reliable forecast of the future budget impact of orphan
drugs in Latvia. Further research is needed to identify the
trends of orphan drugs, including the detailed information
on the availability and accessibility of orphan drugs (in-
cluding the time lag between the orphan drug marketing
approval in the EU and the inclusion in the reimburse-
ment system in Latvia), the potential patient population,
and the prices of orphan drugs.
Limitations
A limitation of the current study is, in fact, that the an-
nual per patient expenditures were estimated from the
payer’s (NHS) perspective only. For drugs providedTable 5 Annual growth rates
Expenditure 2010–2011
Orphan drugs (all) 23.52 %
Orphan drugs (excl. Glivec) 47.73 %
Total pharmaceutical market 4.88 %
Total drug reimbursement budget 11.61 %within the individual reimbursement system the actual
drug costs may be much higher, considering the limit of
EUR 14 229 per patient per year covered by the NHS. If
the drug cost exceeds this limit, the rest of expenses
should be covered by the manufacturers, charities or pa-
tients. Information concerning the expenses not covered
by the NHS is not publicly available, although it should
not have direct impact on Latvian healthcare budget.
Thus, for orphan drugs reimbursed individually the an-
nual per patient expenditures may be considered as the
actual drug costs, only if the above mentioned limit
was not exceeded, i.e. for Revatio, Diacomit, Cystadane,
Wilzin, and Mozobil.
Another limitation of our study can be found in the
different approach for estimating the number of patients
receiving particular drugs. For the individual reimburse-
ment and the CCUH program this number was known
from the NHS reports, while for orphan drugs included
in one of the reimbursement lists the number of drug
packages reimbursed by the NHS was known instead.
To estimate the number of patients receiving such drugs
we considered the recommended maintenance daily
doses used for the main indications in adults. Therefore,
the estimated number of patients for Sprycel and
Tasigna (indicated in adults only) could be closer to the
actual number of patients than for Glivec and Wilzin,
which are indicated in both, adult and pediatric patients.
It should be noted that not all patients are treated for a
whole year and with the recommended maintenance
doses. Additionally, for drugs used for Ph+ CML treat-
ment the main indication was considered Ph+ CML in
chronic phase, rather than accelerated or blast phases.
Conclusions
Latvia is in a position of “a small market within the small
market” or “ultra-small market” for orphan drugs, consid-
ering the small population, low GDP, healthcare budget
constraints, and imperfections in drug reimbursement sys-
tem. Currently, budget impact of orphan drugs in Latvia is
very small compared to other European countries. Orphan
drug expenditure is expected to increase in the future, as
more orphan drugs will become available, both at
European and Latvian level. However, in the long run, the
growth rate of the orphan drug expenditure is expected to
diminish and level off, as patents and marketing exclusiv-
ity of existing orphan drugs will expire. It is, therefore,2011–2012 2012–2013 2013–2014
20.16 % −30.01 % 23.16 %
70.67 % 23.00 % 23.16 %
1.82 % 4.10 % 2.75 %
−1.01 % 0.32 % 4.21 %
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will remain sustainable and relatively small.
Patient access to rare disease therapies in Latvia needs to
be improved considering the disease severity and unmet
medical needs, while the orphan drug expenditure should
be efficiently managed. This is challenging but achievable
through enhanced cooperation between all stakeholders
and implementation of different reimbursement mecha-
nisms, such as various types of risk-sharing agreements
and conditional reimbursement programs, which link the
reimbursement to health and economic outcomes. These
mechanisms can be combined with rare disease registers
and post-marketing surveillance programs that capture
clinical and economic data and monitor orphan drug
uptake. In this context, international cooperation and
European collaboration are of crucial importance.
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